Want to see AU:IMU full AI Analyst Report?
IMU Stock Chart & Stats
AU$0.33
>-AU$0.01(-2.22%)
At close: 4:00 PM EST
AU$0.33
>-AU$0.01(-2.22%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.46
Previous CloseN/A
Volume11.90M
Average Volume (3M)877.83K
Market Cap
AU$45.05M
Enterprise ValueAU$97.38
Total Cash (Recent Filing)AU$14.14M
Total Debt (Recent Filing)AU$5.02M
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Sep 02, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding489,719,850
10 Day Avg. Volume850,615
30 Day Avg. Volume877,834
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside-24.24% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.07
Revenue Forecast (FY)AU$2.50M
Bulls Say, Bears Say
Bulls Say
Diversified Immuno-oncology PipelineImugene's multi-platform pipeline (oncolytic viruses, B-cell activating therapies, CAR-T/engagers) spreads scientific and clinical risk across modalities. This provides multiple longer-term value inflection points and makes the company a more attractive partner for licensing or co-development.
Low Leverage / Conservative Balance SheetA debt-to-equity ratio of 0.24 indicates limited financial leverage, reducing interest burden and default risk. For a clinical-stage biotech, lower leverage preserves flexibility to fund R&D via equity or partnerships and supports negotiating power with potential collaborators over the medium term.
Free Cash Flow Above Net IncomeA free cash flow to net income ratio >1 implies free cash flow exceeds accounting net loss in the reported period. This suggests some positive cash conversion despite accounting losses, providing a modest structural cushion to support continued clinical activity and extending runway relative to net income alone.
Bears Say
Steep Revenue DeclineA dramatic revenue decline weakens the company's ability to self-fund development and signals absence of recurring commercial income. Over months, collapsing top-line undermines operating flexibility and increases reliance on equity raises or partner deals to sustain clinical programs and milestones.
Negative Operating Cash FlowPersistently negative operating cash flow is a structural risk for a development-stage biotech: it depletes reserves and forces financing or deal-making. Without sustained improvement, negative operating cash flow limits the company's ability to run trials independently and can lead to dilution or constrained program timelines.
Deep Losses And Poor Return On EquityDeep negative margins and an ROE of -153% show the company is not generating returns on invested capital. Over time, sustained losses erode equity, reduce investor confidence, and complicate fundraising and partnering, making it harder to finance the costly clinical development needed to realize pipeline value.
Imugene News
IMU FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest share price was AU$0.09 and its highest was AU$0.46 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is AU$45.05M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Sep 02, 2026 which is in 42 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Feb 25, 2026. The company reported -AU$0.13 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.21.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Overvalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate is -0.04.
How many shares outstanding does Imugene have?
Imugene has 489,719,850 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -AU$0.13 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in AU:IMU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (-24.24% Downside)
AU$0.25 (-24.24% Downside)
Blogger Sentiment
Neutral
AU:IMU Sentiment 58%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth AU$89.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.71%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.73%
Trailing 12-Months
Company Description
Imugene
Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.
IMU Stock 12 Month Forecast
Average Price Target
AU$0.25
▼(-24.24% Downside)
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―